NURIX THERAPEUTICS INC. - COMMON STOCK

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

09 يوليو 2025 13:01:00 بحسب Nasdaq GlobeNewswire

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

07 يوليو 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 يونيو 2025 13:01:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

12 يونيو 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

06 يونيو 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Sanofi Exercises License Extension Option to Nurix’s STAT6 Program

02 يونيو 2025 04:00:05 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

28 مايو 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16 مايو 2025 13:00:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

15 مايو 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

14 مايو 2025 06:30:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

28 أبريل 2025 13:00:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

25 أبريل 2025 10:00:00 بحسب Nasdaq GlobeNewswire

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

17 أبريل 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 أبريل 2025 13:01:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

08 أبريل 2025 13:00:00 بحسب Nasdaq GlobeNewswire

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

02 أبريل 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

25 مارس 2025 13:30:00 بحسب Nasdaq GlobeNewswire

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

17 مارس 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 مارس 2025 13:00:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

13 مارس 2025 13:00:00 بحسب Nasdaq GlobeNewswire